Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -736.46% is 75% below its 5-year average of -420.22%, near the high end of its 5-year range (-9080.79%–50.00%).
4.81% below its 12-month average of -702.69%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -203.20%.
GROSS MARGIN
-736.46%
GROSS MARGIN AVG TTM
-702.69%
GROSS MARGIN AVG 3Y
-126.55%
GROSS MARGIN AVG 5Y
-420.22%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.81%
CURRENT VS 3Y AVG
-481.95%
CURRENT VS 5Y AVG
-75.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.03%
median of 851 covered companies
CURRENT VS SECTOR MEDIAN
-1894.93%
vs the sector median at left
Humacyte, Inc.
Market Cap
$82.37M
Gross Margin
-736.46%
TTM Avg
-702.69%
3Y Avg
-126.55%
5Y Avg
-420.22%
Market Cap
$82.08M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$80.84M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$83.91M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$84.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-39721.34%
Market Cap
$80.47M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $82.37M | -736.46% | -702.69% | -126.55% | -420.22% |
| LENSAR Inc (LNSR)vs › | $82.66M | 47.96% | 47.37% | 50.31% | 51.06% |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.08M | 100.00% | 100.00% | 100.00% | 100.00% |
| MediciNova, Inc. (MNOV)vs › | $81.74M | 7.58% | 3.79% | 26.89% | 34.60% |
| Nutriband Inc. (NTRB)vs › | $81.14M | 33.14% | 30.24% | 34.48% | 35.28% |
| Citius Oncology, Inc. (CTOR)vs › | $80.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $83.91M | 0.00% | 0.00% | 0.00% | 0.00% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.04M | 0.00% | 0.00% | 0.00% | -39721.34% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.47M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.50M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
-736.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -203.20% |
| 2026-03-31 | -311.72% |
| 2025-12-31 | -2227.62% |
| 2025-09-30 | -182.20% |
| 2025-06-30 | -588.70% |
| 2025-03-31 | -282.79% |
| 2024-12-31 | 50.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | -6503.23% |
| 2022-06-30 | -1026.21% |
| 2022-03-31 | -780.26% |
| 2021-12-31 | -9080.79% |
| 2021-09-30 | -6284.23% |
| 2021-06-30 | -2011.30% |
| 2021-03-31 | -903.23% |
| 2020-12-31 | -10544.35% |
| 2020-09-30 | -1507.44% |
| 2020-06-30 | -5871.21% |
| 2020-03-31 | -5532.94% |
| 2019-12-31 | 0.00% |
